XML 33 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies - Additional Information (Details)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2016
USD ($)
segment
$ / shares
shares
Sep. 30, 2015
USD ($)
shares
Sep. 30, 2016
USD ($)
$ / shares
shares
Sep. 30, 2015
USD ($)
shares
Line of Credit Facility [Line Items]        
Impairment loss on investments $ 0 $ 5,485 $ 0 $ 5,485
Anti-dilutive securities excluded from computation of earnings per share amount | shares 106 1,786 106 1,786
Contract manufacturing revenue $ 6,345 $ 8,860 $ 17,537 $ 19,044
Number of business segments | segment 1      
Continuing Operations        
Line of Credit Facility [Line Items]        
Contract manufacturing revenue $ (200)   $ 600  
Change in estimate, effect of change on earnings per share | $ / shares $ (0.01)   $ 0.02  
Zohydro ER and Sumavel DosePro        
Line of Credit Facility [Line Items]        
Period to accept returned unused product prior to expiration     6 months  
Period to accept returned unused product after product expiration     12 months  
Endo Ventures Supply Agreement | Minimum        
Line of Credit Facility [Line Items]        
Term of supply agreement     8 years  
Equity Securities        
Line of Credit Facility [Line Items]        
Impairment loss on investments   $ 5,485   $ 5,485